Costo per NNT di upadacitinib nel trattamento dei pazienti con dermatite atopica da moderata a severa in Italia.

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment Pub Date : 2024-02-16 eCollection Date: 2024-01-01 DOI:10.33393/grhta.2024.2728

Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio

引用次数: 0

查看原文本刊更多论文

意大利奥达帕替尼治疗中重度特应性皮炎患者的每 NNT 成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Global & Regional Health Technology Assessment HEALTH CARE SCIENCES & SERVICES-

CiteScore

0.80

自引率

20.00%

发文量

审稿时长

8 weeks

期刊介绍： Global & Regional Health Technology Assessment (GRHTA) is a peer-reviewed, open access journal which aims to promote health technology assessment and economic evaluation, enabling choices among alternative therapeutical paths or procedures with different clinical and economic outcomes. GRHTA is a unique journal having three different editorial boards who focus on their respective geographical expertise.